Next-Generation Strategies for Overcoming Physiological and Cellular Barriers to Achieve Effective Targeted Drug Delivery

Introduction

The development of effective drug delivery systems remains one of the most critical challenges in modern pharmaceutical science. Although substantial progress has been made in drug discovery and molecular therapeutics, the successful translation of these agents into clinically effective treatments is often limited by inefficient delivery to the intended site of action. Conventional drug administration methods, including oral and intravenous routes, frequently result in non-specific biodistribution, rapid systemic clearance, suboptimal bioavailability, and dose-limiting toxicity [1]. Consequently, therapeutic outcomes are compromised, and adverse side effects increase, particularly in the treatment of cancer, neurological disorders, infectious diseases, and chronic inflammatory conditions. Targeted drug delivery has emerged as a transformative strategy aimed at enhancing therapeutic precision while minimizing off-target effects. The central objective is to selectively accumulate therapeutic agents at diseased tissues, maintain optimal drug concentration for a sustained duration, and reduce systemic exposure [2]. However, achieving this goal requires navigating a complex cascade of biological barriers that operate at multiple levels, from systemic circulation to intracellular compartments. These barriers, while essential for physiological protection and homeostasis, significantly restrict the efficiency of drug transport and localization [3]. Physiological barriers include enzymatic degradation in the gastrointestinal tract, rapid renal and hepatic clearance, immune surveillance by the mononuclear phagocyte system, vascular endothelial tight junctions such as those found in the blood–brain barrier, and abnormal tissue architecture in pathological states such as tumors. At the cellular level, drug molecules must overcome membrane impermeability, endosomal entrapment, lysosomal degradation, and limited nuclear access for gene-based therapeutics. Each barrier represents a distinct challenge that requires tailored engineering solutions.

The limitations of conventional formulations have catalyzed the evolution of advanced drug delivery platforms, particularly nanotechnology-based systems. Nanocarriers—including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, micelles, and inorganic nanostructures—offer unique physicochemical properties such as tunable size, surface charge, morphology, and functionalization capacity. These attributes enable improved pharmacokinetics, enhanced permeability, controlled release, and molecular targeting. Importantly, nanoscale systems can be engineered to interact dynamically with biological environments, enabling stimuli-responsive behavior and adaptive functionality.

The nanotechnology, emerging strategies such as biomimetic systems, exosome-mediated delivery, cell-penetrating peptides, microenvironment-responsive carriers, and artificial intelligence (AI)-assisted formulation design are redefining the landscape of targeted therapeutics. Biomimetic approaches utilize natural cell membranes or endogenous vesicles to evade immune recognition and improve biocompatibility. Smart delivery systems respond to disease-specific cues such as acidic pH, hypoxia, enzymatic overexpression, or redox gradients, enabling precise spatial and temporal drug release. Meanwhile, AI-driven predictive modeling accelerates rational design by optimizing carrier composition, ligand selection, and pharmacokinetic behavior.

Recent advances in molecular medicine—including RNA therapeutics, CRISPR-based gene editing, immunotherapy, and personalized medicine—have further emphasized the urgent need for sophisticated delivery technologies [4-5]. Many of these novel therapeutics are highly sensitive, large, or biologically unstable, making them particularly susceptible to degradation and clearance. Without efficient delivery systems, their clinical potential cannot be fully realized. The major translational challenges remain. Issues related to long-term toxicity, large-scale manufacturing, reproducibility, regulatory approval, and interpatient variability must be addressed to ensure safe and effective clinical application. Therefore, a comprehensive understanding of the physiological and cellular barriers to drug delivery, along with next-generation strategies to overcome them, is essential for advancing the field.

2. Major Physiological Barriers to Drug Delivery

Effective targeted drug delivery is fundamentally constrained by a series of highly evolved physiological defense mechanisms designed to maintain homeostasis and protect the body from foreign substances. While these barriers are essential for survival, they significantly limit therapeutic efficiency, particularly for biologics, macromolecules, and nanoparticle-based systems.

2.1 Gastrointestinal and Mucosal Barriers

For orally administered therapeutics, the gastrointestinal (GI) tract presents multiple sequential obstacles. The acidic gastric environment (pH 1–3) promotes degradation of acid-labile drugs, while digestive enzymes such as proteases and lipases rapidly break down peptides, proteins, and lipid-based carriers. Beyond chemical instability, the intestinal mucus layer acts as a viscoelastic diffusion barrier, trapping particulate systems and preventing direct epithelial contact [6]. Tight junctions between epithelial cells further restrict paracellular transport, particularly for hydrophilic and high-molecular-weight compounds. Efflux transporters such as P-glycoprotein actively pump drugs back into the intestinal lumen, reducing net absorption. Additionally, first-pass hepatic metabolism significantly decreases systemic bioavailability of many orally delivered drugs. These combined barriers make oral delivery of complex therapeutics particularly challenging.

2.2 Mononuclear Phagocyte System (MPS) and Systemic Clearance

Upon intravenous administration, drug carriers encounter rapid immune surveillance. Plasma proteins adsorb onto nanoparticle surfaces, forming a “protein corona” that alters their biological identity and promotes recognition by macrophages in the liver (Kupffer cells), spleen, and bone marrow. This process, mediated by the mononuclear phagocyte system (MPS), leads to rapid clearance from systemic circulation. Complement activation may further accelerate opsonization and immune recognition [7]. As a result, circulation half-life is significantly reduced, limiting the probability of nanoparticles reaching target tissues. Moreover, renal filtration eliminates small molecules and particles below the glomerular size threshold, while hepatic metabolism degrades many lipophilic compounds. Therefore, maintaining optimal particle size, surface chemistry, and hydrophilicity is essential to prolong systemic persistence.

2.3 Blood–Brain Barrier (BBB)

The blood–brain barrier represents one of the most restrictive biological barriers in the human body. Formed by tightly connected endothelial cells supported by astrocytes and pericytes, the BBB prevents passive diffusion of most hydrophilic and large molecules into the central nervous system (CNS). Tight junction proteins such as claudins and occludins eliminate paracellular transport, while efflux transporters including P-glycoprotein and breast cancer resistance protein actively remove xenobiotics [8]. Enzymatic activity within endothelial cells further metabolizes many therapeutic agents. Consequently, over 98% of small-molecule drugs and nearly all biologics fail to cross the BBB effectively. This presents a major obstacle in the treatment of neurodegenerative disorders, brain tumors, epilepsy, and psychiatric diseases.

2.4 Tumor Microenvironment (TME)

Although tumors are often characterized by enhanced permeability and retention (EPR) effects, the tumor microenvironment remains a significant barrier to uniform drug distribution. Tumor vasculature is irregular, leaky, and poorly organized, resulting in heterogeneous blood flow [9]. Elevated interstitial fluid pressure reduces convective transport into deeper tumor regions. Dense extracellular matrix components such as collagen and hyaluronic acid create mechanical resistance to nanoparticle penetration. Hypoxia and acidic pH further complicate drug stability and activity. Additionally, tumor heterogeneity leads to variable receptor expression, reducing the efficiency of ligand-mediated targeting strategies. These factors collectively limit deep tissue penetration and therapeutic uniformity.

2.5 Cellular and Intracellular Barriers

Even after reaching the target tissue, drug molecules must traverse cellular membranes to exert their therapeutic effects. The phospholipid bilayer restricts entry of hydrophilic macromolecules, requiring active transport or endocytosis. Once internalized, many delivery systems become trapped within endosomes and are subsequently degraded in lysosomes due to acidic pH and hydrolytic enzymes [10]. For nucleic acid therapeutics, additional barriers include cytoplasmic nuclease degradation and limited nuclear membrane penetration. Inefficient endosomal escape remains one of the principal bottlenecks in gene and RNA-based therapies.

3. Next-Generation Strategies to Overcome Physiological Barriers

To address the multifaceted barriers described above, innovative delivery systems have been developed that combine material engineering, molecular targeting, and responsive design [11]. These next-generation strategies aim not only to bypass biological obstacles but also to actively exploit them for improved targeting.

3.1 Surface Engineering and Stealth Nanocarriers

One of the most successful approaches to prolong systemic circulation involves surface modification of nanocarriers. Polyethylene glycol (PEGylation) reduces protein adsorption and macrophage recognition by creating a hydrophilic steric shield. Similarly, zwitterionic and hydrophilic polymer coatings minimize opsonization and immune clearance [12]. By reducing MPS uptake, stealth nanoparticles exhibit extended half-life and enhanced accumulation in target tissues via passive targeting mechanisms. Advanced surface engineering now focuses on dynamic coatings that detach or transform upon reaching the target microenvironment, balancing immune evasion with efficient cellular uptake.

3.2 Ligand-Mediated Active Targeting

Active targeting involves functionalizing drug carriers with ligands that bind specifically to overexpressed receptors on diseased cells. Antibodies, antibody fragments, peptides, aptamers, and small molecules such as folic acid or transferrin are commonly used targeting moieties. Upon ligand–receptor interaction, the drug carrier undergoes receptor-mediated endocytosis, increasing intracellular delivery efficiency. This strategy enhances specificity, particularly in cancer therapy, where tumor cells overexpress receptors such as HER2, EGFR, or integrins. However, challenges such as receptor heterogeneity and ligand immunogenicity must be carefully addressed.

3.3 Stimuli-Responsive and Smart Delivery Systems

Smart drug delivery systems are engineered to respond to specific physiological triggers, enabling controlled and localized drug release. pH-responsive carriers exploit the acidic environment of tumors and endosomes to release payloads selectively [13]. Redox-sensitive systems utilize elevated intracellular glutathione levels to trigger drug release. Enzyme-responsive platforms degrade in the presence of disease-associated proteases. External stimuli such as light, ultrasound, magnetic fields, and temperature can also activate drug release in a spatially controlled manner. These approaches improve therapeutic precision while minimizing systemic toxicity.

3.4 Blood–Brain Barrier Penetration Strategies

To overcome BBB restrictions, receptor-mediated transcytosis has emerged as a promising technique. By conjugating ligands targeting transferrin or insulin receptors, nanocarriers can exploit endogenous transport pathways across endothelial cells. Focused ultrasound combined with microbubbles temporarily disrupts tight junctions, allowing localized drug entry [14]. Intranasal delivery offers a non-invasive route via olfactory and trigeminal neural pathways, bypassing systemic circulation. Exosome-based delivery systems, due to their natural origin and intrinsic ability to cross the BBB, are gaining considerable attention for CNS therapeutics.

3.5 Endosomal Escape and Intracellular Targeting

Efficient intracellular delivery requires escape from endosomal compartments before lysosomal degradation. The proton sponge effect, commonly associated with cationic polymers such as polyethyleneimine (PEI), induces osmotic swelling and rupture of endosomes. pH-sensitive fusogenic lipids and membrane-disruptive peptides also facilitate cytoplasmic release. For gene therapies, nuclear localization signals enhance transport across the nuclear envelope. Combining targeting ligands with intracellular trafficking signals significantly improves therapeutic efficacy.

3.6 Biomimetic and Cell-Derived Systems

Biomimetic approaches utilize natural cell membranes to camouflage nanoparticles, thereby reducing immune recognition and prolonging circulation time. Red blood cell membrane-coated nanoparticles exhibit extended half-life, while cancer cell membrane-coated systems enable homotypic targeting. Exosomes and extracellular vesicles provide inherent biocompatibility and efficient cellular uptake. Cell-mediated delivery using macrophages or stem cells leverages natural homing properties to transport therapeutics to inflamed or tumor tissues.

4. Overcoming Cellular and Intracellular Barriers

Even after successful navigation through systemic physiological barriers and accumulation at the target tissue, therapeutic agents must overcome a series of cellular and intracellular obstacles to achieve their intended pharmacological effect. The cellular plasma membrane represents the first major barrier at this stage. Composed of a phospholipid bilayer embedded with membrane proteins, it selectively regulates molecular transport, restricting passive diffusion primarily to small, lipophilic molecules. Hydrophilic drugs, macromolecules, peptides, proteins, and nucleic acids require active transport mechanisms or endocytosis for cellular entry. However, receptor-mediated endocytosis often leads to sequestration within endosomes, creating an additional bottleneck for effective cytoplasmic delivery. Endosomal entrapment remains one of the most significant limitations in intracellular drug delivery, particularly for gene therapies and RNA-based therapeutics. Following internalization, drug carriers are typically trafficked through early endosomes, late endosomes, and ultimately lysosomes, where acidic pH and hydrolytic enzymes promote degradation of the therapeutic payload [15]. To address this issue, next-generation delivery systems are engineered with endosomal escape mechanisms. The proton sponge effect, commonly associated with cationic polymers such as polyethyleneimine (PEI), induces osmotic swelling and rupture of endosomal membranes, facilitating cytoplasmic release. Similarly, pH-sensitive lipids and fusogenic peptides destabilize endosomal membranes under acidic conditions, enabling efficient drug escape. For nucleic acid therapeutics, intracellular delivery poses additional challenges. Once in the cytoplasm, DNA-based therapeutics must cross the nuclear envelope to enable transcription, a process that is highly regulated and typically restricted to dividing cells. To enhance nuclear localization, delivery systems incorporate nuclear localization signals (NLS) or utilize viral-mimetic strategies that exploit natural intracellular trafficking pathways. In the case of small interfering RNA (siRNA) and messenger RNA (mRNA), cytoplasmic stability and protection from nucleases are critical. Lipid nanoparticles and polymeric carriers have demonstrated considerable success in shielding RNA molecules while promoting efficient translation. Collectively, advances in intracellular targeting strategies are essential to maximize therapeutic efficacy and minimize degradation losses.

5. Biomimetic and Cell-Mediated Delivery Systems

Biomimetic drug delivery systems represent a paradigm shift in overcoming immune recognition and enhancing target specificity by emulating natural biological structures. Unlike synthetic nanoparticles that may trigger immune responses or rapid clearance, biomimetic platforms utilize components derived from natural cells to improve compatibility and functional performance. One of the most promising approaches involves coating nanoparticles with natural cell membranes, such as those derived from red blood cells, platelets, leukocytes, or cancer cells. These membrane-coated nanoparticles inherit the surface proteins and antigens of their source cells, enabling immune evasion, prolonged circulation, and, in some cases, homotypic targeting.

Red blood cell membrane-coated nanoparticles exhibit extended systemic half-life due to their ability to avoid macrophage recognition [16]. Platelet membrane-coated systems can target damaged vasculature and circulating tumor cells by exploiting natural adhesion molecules. Similarly, cancer cell membrane-coated nanoparticles enable homotypic targeting, whereby tumor-derived membrane proteins facilitate selective binding to primary or metastatic tumor cells. These strategies enhance accumulation at the disease site while reducing off-target interactions. Exosome-based delivery systems have also gained significant attention as natural nanocarriers capable of intercellular communication. Exosomes are endogenous extracellular vesicles that transport proteins, lipids, and nucleic acids between cells. Their intrinsic biocompatibility, low immunogenicity, and inherent targeting capabilities make them attractive vehicles for delivering RNA, proteins, and small-molecule drugs. Furthermore, immune cells such as macrophages and mesenchymal stem cells have been explored as living drug carriers. These cells possess natural homing properties toward inflamed or tumor tissues, allowing them to transport therapeutic payloads across physiological barriers. By leveraging biological systems rather than opposing them, biomimetic and cell-mediated approaches offer a promising avenue for next-generation targeted drug delivery.

6. Microenvironment Modulation and Barrier-Transforming Strategies

In addition to bypassing biological barriers, emerging delivery strategies aim to actively modify or normalize the pathological microenvironment to enhance therapeutic penetration and effectiveness. This approach is particularly relevant in oncology, where the tumor microenvironment (TME) presents structural and biochemical obstacles that limit drug distribution. The extracellular matrix (ECM), composed of dense collagen networks and glycosaminoglycans such as hyaluronic acid, restricts nanoparticle diffusion and increases interstitial fluid pressure. To overcome these mechanical barriers, researchers have developed nanoparticles capable of co-delivering matrix-degrading enzymes, such as collagenase or hyaluronidase, to temporarily loosen ECM structure and improve deep tissue penetration [17]. Abnormal tumor vasculature further contributes to heterogeneous perfusion and hypoxia. Strategies aimed at vascular normalization seek to restore more organized and functional blood vessel architecture, thereby enhancing drug transport. Hypoxia-responsive drug systems exploit low oxygen levels in tumors to activate prodrugs selectively within hypoxic regions, improving specificity and reducing systemic toxicity. Similarly, pH-responsive platforms capitalize on the acidic tumor microenvironment to trigger localized drug release. Beyond oncology, inflammatory and fibrotic microenvironments in chronic diseases also present altered biochemical conditions that can be therapeutically exploited. Reactive oxygen species (ROS)-responsive systems release drugs in oxidative environments, while enzyme-responsive carriers degrade in the presence of disease-associated proteases. These barrier-transforming strategies represent a shift from passive adaptation to active modulation, enabling deeper tissue penetration and improved therapeutic outcomes, microenvironment-targeted and barrier-modulating systems enhance the efficiency of drug delivery by not only navigating physiological obstacles but also reshaping pathological conditions to favor therapeutic success.

7. Artificial Intelligence and Computational Optimization

Artificial intelligence (AI) and computational modeling are transforming the design and optimization of targeted drug delivery systems. Traditional formulation development often relies on empirical trial-and-error approaches, which are time-consuming and resource-intensive. AI-driven platforms enable predictive modeling of nanoparticle behavior in biological environments, significantly accelerating rational design.

Machine learning algorithms can predict nanoparticle–protein corona formation, which critically influences biodistribution, immune recognition, and targeting efficiency. Computational tools also optimize physicochemical parameters such as particle size, surface charge, hydrophobicity, and ligand density to improve circulation time and cellular uptake [18]. In addition, in silico simulations allow prediction of pharmacokinetic and pharmacodynamic profiles before in vivo testing. AI-assisted screening of ligand–receptor interactions further enhances active targeting specificity. Collectively, these tools reduce developmental costs, improve reproducibility, and enhance translational success.

8. Safety, Regulatory, and Translational Challenges

Despite significant technological advances, several challenges hinder the clinical translation of next-generation drug delivery systems. Long-term toxicity remains a major concern, particularly for inorganic nanoparticles and non-biodegradable materials that may accumulate in organs such as the liver and spleen. Immunogenicity and unexpected inflammatory responses can further compromise safety. Manufacturing scalability presents another limitation, as complex multifunctional nanocarriers often require highly controlled synthesis processes [19-22]. Batch-to-batch variability can affect therapeutic performance and regulatory approval. Moreover, current regulatory frameworks are not fully adapted to evaluate multifunctional nanomedicines that combine targeting, imaging, and therapeutic functions. Standardized characterization protocols and harmonized global regulatory guidelines are essential to facilitate commercialization and clinical adoption.

9. Future Perspectives

The future of targeted drug delivery is closely aligned with the principles of precision medicine. Patient-specific targeting strategies based on genetic, molecular, and biomarker profiling will enable more individualized therapies. Multifunctional theranostic systems that integrate diagnostic imaging with therapeutic delivery are expected to enhance treatment monitoring and response prediction. Emerging modalities such as CRISPR-based gene editing and RNA therapeutics require highly efficient and safe delivery platforms, further driving innovation in nanocarrier design. AI-optimized, personalized nanomedicines may soon allow real-time adaptation of formulations based on patient-specific data. Additionally, the development of biodegradable, biocompatible, and environmentally sustainable biomaterials will play a critical role in improving safety and long-term clinical acceptance. Future systems will likely combine targeting, controlled release, imaging capability, and immune modulation within a single integrated platform.

10. Conclusion

Overcoming physiological and cellular barriers remains fundamental to achieving effective targeted drug delivery. Biological defense mechanisms, while essential for maintaining homeostasis, significantly limit drug bioavailability and tissue specificity. Advances in nanotechnology, biomimetic engineering, smart materials, and artificial intelligence have expanded the possibilities for precise and controlled therapeutic delivery. An integrating multidisciplinary innovations, next-generation delivery systems offer improved specificity, reduced systemic toxicity, and enhanced therapeutic efficacy. However, continued research into safety, scalability, and regulatory standardization is necessary to ensure successful clinical translation. With sustained technological and scientific progress, targeted drug delivery platforms are poised to play a transformative role in the future of precision therapeutics.

References

1. Li, Y., Li, X. M., Wei, L. S., & Ye, J. F. (2024). Advancements in mitochondrial-targeted nanotherapeutics: overcoming biological obstacles and optimizing drug delivery. Frontiers in Immunology, 15, 1451989.
2. Thomas, O. S., & Weber, W. (2019). Overcoming physiological barriers to nanoparticle delivery—are we there yet?. Frontiers in Bioengineering and Biotechnology, 7, 415.
3. Zhou, Y., Chen, X., Cao, J., & Gao, H. (2020). Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy. Journal of Materials Chemistry B, 8(31), 6765-6781.
4. Lee, H., & Noh, H. (2023). Advancements in nanogels for enhanced ocular drug delivery: cutting-edge strategies to overcome eye barriers. Gels, 9(9), 718.
5. Deshmukh, Rohitas, Pranshul Sethi, Bhupendra Singh, Jailani Shiekmydeen, Sagar Salave, Ravish J. Patel, Nemat Ali, Summya Rashid, Gehan M. Elossaily, and Arun Kumar. “Recent review on biological barriers and host–material interfaces in precision drug delivery: advancement in biomaterial engineering for better treatment therapies.” Pharmaceutics 16, no. 8 (2024): 1076.
6. Ezike, Tobechukwu Christian, Ugochukwu Solomon Okpala, Ufedo Lovet Onoja, Chinenye Princess Nwike, Emmanuel Chimeh Ezeako, Osinachi Juliet Okpara, Charles Chinkwere Okoroafor et al. “Advances in drug delivery systems, challenges and future directions.” Heliyon 9, no. 6 (2023).
7. Kievit, F. M., & Zhang, M. (2011). Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Advanced materials, 23(36), H217-H247.
8. Peng, B., Li, H., & Peng, X. X. (2023). Call for next-generation drugs that remove the uptake barrier to combat antibiotic resistance. Drug Discovery Today, 28(10), 103753.
9. Cheng, X., Xie, Q., & Sun, Y. (2023). Advances in nanomaterial-based targeted drug delivery systems. Frontiers in bioengineering and biotechnology, 11, 1177151.
10. Elliott, R. O., & He, M. (2021). Unlocking the power of exosomes for crossing biological barriers in drug delivery. Pharmaceutics, 13(1), 122.
11. Tan, J. S., Jaffar Ali, M. N. B., Gan, B. K., & Tan, W. S. (2023). Next-generation viral nanoparticles for targeted delivery of therapeutics: Fundamentals, methods, biomedical applications, and challenges. Expert Opinion on Drug Delivery, 20(7), 955-978.
12. Zhou, L., Zou, M., Xu, Y., Lin, P., Lei, C., & Xia, X. (2022). Nano drug delivery system for tumor immunotherapy: next-generation therapeutics. Frontiers in oncology, 12, 864301.
13. Khalid, A., Persano, S., Shen, H., Zhao, Y., Blanco, E., Ferrari, M., & Wolfram, J. (2017). Strategies for improving drug delivery: nanocarriers and microenvironmental priming. Expert opinion on drug delivery, 14(7), 865-877.
14. Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021). Extracellular vesicles as a next-generation drug delivery platform. Nature nanotechnology, 16(7), 748-759.
15. Bor, G., & Hosta‐Rigau, L. (2023). Next generation of brain cancer nanomedicines to overcome the blood–brain barrier (BBB): Insights on transcytosis, perivascular tumor growth, and BBB models. Advanced Therapeutics, 6(12), 2300161.
16. Yassir Musa (2025). The Expanding Role of Artificial Intelligence in Clinical Medical Radiology Practice. Annals of Medical and Health Research: An International Journal. DOI: https://doi.org/10.51470/ARMHR.2025.4.1.09
17. Ghosh, D., Peng, X., Leal, J., & Mohanty, R. P. (2018). Peptides as drug delivery vehicles across biological barriers. Journal of pharmaceutical investigation, 48(1), 89-111.
18. Zarepour, A., Khosravi, A., Iravani, S., & Zarrabi, A. (2024). Biohybrid micro/nanorobots: pioneering the next generation of medical technology. Advanced Healthcare Materials, 13(31), 2402102.
19. Bhujbal, S., Rupenthal, I. D., Patravale, V. B., & Agarwal, P. (2025). Transfersomes: a next-generation drug delivery system for topical ocular drug delivery. Expert Opinion on Drug Delivery, 22(7), 935-956.
20. Kim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J. X. (2010). Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle–cell interaction. Expert opinion on drug delivery, 7(1), 49-62.
21. Muhab Suliman (2025). Advances in Precision Medicine, Pharmacogenomics and Personalized Drug Therapy Approaches. Annals of Medical and Health Research: An International Journal. DOI: https://doi.org/10.51470/ARMHR.2025.4.1.01
22. Dos Santos, A. M., Carvalho, S. G., Meneguin, A. B., Sábio, R. M., Gremião, M. P. D., & Chorilli, M. (2021). Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. Journal of Controlled Release, 334, 353-366.